Biphasic Regulation of Transcription Factor Nuclear Factor-κB Activity in Human Endothelial Cells by Lysophosphatidylcholine Through Protein Kinase C–Mediated Pathway
- 1 April 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (4) , 568-576
- https://doi.org/10.1161/01.atv.18.4.568
Abstract
—Lysophosphatidylcholine (lysoPC), which is generated in oxidized LDL (Ox-LDL) and abundantly exists in atherosclerotic arterial walls, has been shown to alter various endothelial functions and induces several endothelial genes expressed in atherosclerotic arterial walls. Nuclear factor-kappa B (NF-κB), a pleiotropic transcription factor, plays an important role in regulation of expression of various genes implicated in atherosclerosis. We have previously reported that lysoPC transferred from Ox-LDL to endothelial surface membrane activates endothelial protein kinase C (PKC), leading to modulated endothelial functions. This study was aimed at determining whether lysoPC could modulate activity of transcription factors in cultured human umbilical vein endothelial cells (HUVECs) by using electrophoretic mobility shift assay. LysoPC was found to increase DNA-binding activity of NF-κB in HUVECs within 15 minutes, which peaked at 1 to 2 hours and subsequently declined to the baseline level at 6 hours. Lower concentrations (5 to 15 μmol/L) of lysoPC markedly increased NF-κB activity, but higher concentration (50 μmol/L) of lysoPC inhibited the activity. Phorbol 12-myristate 13-acetate, a potent activator of PKC, also augmented NF-κB activity in HUVECs, mimicking the effects of lysoPC; furthermore, calphostin C and chelerythrine chloride, specific PKC inhibitors, and α-tocopherol, a clinically potent PKC inhibitor, suppressed the lysoPC-induced NF-κB activation. These results indicate that lysoPC regulates NF-κB activity in a biphasic manner dependent on its concentrations and incubation time in human endothelial cells and the endothelial PKC activation may in part be involved in the lysoPC-induced NF-κB activation. Thus, the time course and the positive and negative biphasic regulatory actions of lysoPC on NF-κB activity in endothelial cells might exhibit a unique effect of lysoPC in arterial walls on the different stages of atherosclerosis.Keywords
This publication has 49 references indexed in Scilit:
- Chelerythrine is a potent and specific inhibitor of protein kinase CPublished by Elsevier ,2004
- Activation of ICAM-1 promoter by lysophosphatidylcholine: Possible involvement of protein tyrosine kinasesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- CCAAT/Enhancer‐Binding Protein β (C/EBPβ) Binds and Activates While Hepatocyte Nuclear Factor‐4 (HNF‐4) does not Bind but Represses the Liver‐Type Arginase PromoterEuropean Journal of Biochemistry, 1996
- Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosisThe American Journal of Cardiology, 1995
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994
- The role of the endothelium in atherogenesisCurrent Opinion in Lipidology, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase CBiochemical and Biophysical Research Communications, 1989
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976